Treatment with inebilizumab was associated with reduction in aquaporin-4 antibody titers and B cells for those with neuromyelitis optica spectrum disorder, according to an expert at ECTRIMS 2022.
“The prominent role B cells play in [neuromyelitis optica spectrum disorder] disease activity is well-documented at this point, but the relationship between attacks and peripheral B-cell subsets, particularly plasma cells and plasma blasts, has not been as clear,” Bruce A. Cree, MD, PhD, professor of clinical neurology at the Weill Institute for Neurosciences at the University of